Ignite Creation Date:
2024-05-06 @ 8:59 AM
Last Modification Date:
2024-10-26 @ 12:08 PM
Study NCT ID:
NCT02878785
Status:
COMPLETED
Last Update Posted:
2023-03-29
First Post:
2016-08-03
Brief Title:
Decitabine and Talazoparib in Untreated AML and RR AML
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Multicenter Phase 12 Study of Combination Therapy w DNA Methyltransferase Inhibitor Decitabine Poly ADP Ribose Polymerase Inhibitor Talazoparib for Untreated AML in Adults Unfit for Cytotoxic Chemotherapy or RR AML
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
1565GCC
Brief Summary:
The purpose of this study is to find the best way to combine a new chemotherapy drug with one that is already in use to treat AML The new experimental drug is called talazoparib also known as BMN-673 and it is not approved by the Federal Drug Administration FDA The FDA is allowing the use of talazoparib for the purposes of this study
Decitabine is used to treat bone marrow diseases called myelodysplastic syndromes MDS as well as off label for AML
Lab work suggests that talazoparib will increase the effects of decitabine in leukemia cells
Investigators hope that treating patients with decitabine and talazoparib together will be more successful that treating patients with decitabine alone
This study has two parts The purpose of part one the study is to find out the best doses of decitabine and talazoparib to use when they are given together to treat AML The purpose of part two is to see how well the drugs work together to treat AML
All participants in the study will be treated with decitabine and talazoparib
Part one of the study will include as few as two people and as many as 36 people to find the best dose levels of the study drugs Part one will begin enrolling first Part two of the study will not start until the Part one of the study is complete Participants will be told which part of the study they may be enrolled in Part two of the study may include as few as 79 people and as many as 135 people Part two includes three separate arms Participants enrolled in Part two of the study will be assigned to one of the three arms below in order to test the success rate of the study drug dose determined by Part one
Arm A will enroll adult patients with AML who are thought not to be likely to tolerate or respond to standard chemotherapy
Arm B will enroll adult patients with AML that has not responded to previous treatment or has come back after responding to previous treatment
Arm C will enroll adult patients previously treated with a DNA methyltransferase inhibitor decitabine azacitidine or guadecitabine
This is a multi-center study Up to 171 people may take part in this study globally
Decitabine is used to treat bone marrow diseases called myelodysplastic syndromes MDS as well as off label for AML
Lab work suggests that talazoparib will increase the effects of decitabine in leukemia cells
Investigators hope that treating patients with decitabine and talazoparib together will be more successful that treating patients with decitabine alone
This study has two parts The purpose of part one the study is to find out the best doses of decitabine and talazoparib to use when they are given together to treat AML The purpose of part two is to see how well the drugs work together to treat AML
All participants in the study will be treated with decitabine and talazoparib
Part one of the study will include as few as two people and as many as 36 people to find the best dose levels of the study drugs Part one will begin enrolling first Part two of the study will not start until the Part one of the study is complete Participants will be told which part of the study they may be enrolled in Part two of the study may include as few as 79 people and as many as 135 people Part two includes three separate arms Participants enrolled in Part two of the study will be assigned to one of the three arms below in order to test the success rate of the study drug dose determined by Part one
Arm A will enroll adult patients with AML who are thought not to be likely to tolerate or respond to standard chemotherapy
Arm B will enroll adult patients with AML that has not responded to previous treatment or has come back after responding to previous treatment
Arm C will enroll adult patients previously treated with a DNA methyltransferase inhibitor decitabine azacitidine or guadecitabine
This is a multi-center study Up to 171 people may take part in this study globally
Detailed Description:
In this clinical trial investigators combine decitabine and talazoparib in the treatment of patients with AML Decitabine will be given in the established regimen of IV daily dosing for 5 days every 28 days Talazoparib will be initiated orally daily on a continuous basis beginning on Day 1 of Course 1 In this phase 1 trial decitabine and talazoparib will be tested at 3 and 4 dose levels respectively yielding up to 6 combinations Doses will be escalated based on tolerability using a classic 33 design Once the MTD for decitabine combined with 025 mg talazoparib is established the dose of talazoparib will be escalated with the dose of decitabine kept fixed at the provisional MTD dose There is no further stepping up or down of the drugs in the combination
The regimen for phase 2 testing will be chosen based on tolerability but also based on available pharmacodynamic and efficacy data In phase 2 the selected combination regimen will be studied for efficacy
Each patient will be treated until occurrence of either unacceptable toxicity or disease progression Bone marrow aspirate and biopsy will be performed on approximately day 28 of each treatment course unless circulating blasts persist in the peripheral blood until documentation of CR or CRi Bone marrow aspirate and biopsy will then be repeated at time of clinical concern for disease progression
In Phase 1 the clinical trial will enroll patients with relapsed and refractory AML in order to test the novel combination initially in patients with less favorable outcomes with decitabine alone This is being done to avoid the possibility of compromising the outcomes of untreated patients who have up to a 40 response rate to 5-day decitabine as a single agent in the unlikely possibility that the combination is inferior The regimen will then also be tested in previously untreated AML patients unfit for chemotherapy in phase 2
The regimen for phase 2 testing will be chosen based on tolerability but also based on available pharmacodynamic and efficacy data In phase 2 the selected combination regimen will be studied for efficacy
Each patient will be treated until occurrence of either unacceptable toxicity or disease progression Bone marrow aspirate and biopsy will be performed on approximately day 28 of each treatment course unless circulating blasts persist in the peripheral blood until documentation of CR or CRi Bone marrow aspirate and biopsy will then be repeated at time of clinical concern for disease progression
In Phase 1 the clinical trial will enroll patients with relapsed and refractory AML in order to test the novel combination initially in patients with less favorable outcomes with decitabine alone This is being done to avoid the possibility of compromising the outcomes of untreated patients who have up to a 40 response rate to 5-day decitabine as a single agent in the unlikely possibility that the combination is inferior The regimen will then also be tested in previously untreated AML patients unfit for chemotherapy in phase 2
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None